227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC

Peapod Lane Capital LLC bought a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 227,239 shares of the biotechnology company's stock, valued at approximately $550,000. Peapod Lane Capital LLC owned 0.56% of Oramed Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its position in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock valued at $81,000 after acquiring an additional 10,774 shares in the last quarter. BML Capital Management LLC boosted its position in shares of Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company's stock valued at $5,334,000 after purchasing an additional 837,153 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Oramed Pharmaceuticals in the third quarter worth $272,000. Murchinson Ltd. raised its holdings in Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company's stock worth $4,170,000 after purchasing an additional 8,889 shares in the last quarter. Finally, XTX Topco Ltd lifted its position in Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock valued at $60,000 after buying an additional 9,242 shares during the period. Hedge funds and other institutional investors own 12.73% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, February 6th.

Oramed Pharmaceuticals Stock Performance

Shares of Oramed Pharmaceuticals stock traded down $0.05 during midday trading on Monday, hitting $2.40. The company had a trading volume of 126,563 shares, compared to its average volume of 108,058. Oramed Pharmaceuticals Inc. has a 52-week low of $2.00 and a 52-week high of $3.67. The stock has a market capitalization of $96.74 million, a P/E ratio of 21.82 and a beta of 1.66. The company has a 50 day moving average of $2.35 and a 200 day moving average of $2.37.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.